takeaway ceo/cfo call replay
 continu barclay biopharma ceo/cfo confer call seri host svp cfo rob michael replay
call avail us ou passcod call focus ou humira eros
curv outlook us sale new asset opportun oncolog omen hcv key takeaw ay
broken
remain confid guid y/i ou humira eros impact reiter ou biosimilar
eros curv continu play line ith compani recent expect guidanc year sale ere
dow y/i oper basi ith price eros expect throughout year greater declin like
move forw ard manag caution origin analogu ere base enbrel remicad hich account
steeper price reduct overal continu slightli conserv forecast sale y/i vs
consensu
ou dynam impact market without annual tender ad color on-going ou market dynam report
although market base tender system usual lock annual cycl major marketsinclud germani
spain italyar dynam ith price movement expect throughout year still reiter good handl
geographi expect abl compet favor recent global updat hich incorpor
updat see biopharmaceut global inflamm immunolog model updat
outlook us biosimilar harder predict given lack analogu market like evolv ahead launch
regard outlook us caution analogu exist ad complex major humira us
sold specialti pharmaci mani hich ow ned pbm hich adher formulariesw hich
potenti moder impact biosimilar compar market ith inner-take-al tender system manag conced
dynam like shift approach us biosimilar launch dateand larg number player may
neg impact outlook expect interchang ell forecast us y/i declin
follow ed y/i thereaft vs consensu respect
drug price rebat reform unlik impact humira outlook emphas on-going drug price rebat
reform debat unlik impact overal outlook humira manag continu believ discount tie formulari
access like drive volum ith formulari overal effect cost manag tool still compani remain support
low ere out-of-pocket cost consum recent coverag on-going debat see thought
today senat hear drug price thought hh rebat propos
opportun skyrizi upadacitinib exist later- early-lin sit note hen provid long-term
guidanc skyrizi upadacitinib posit data tnf-failur popul support grow th high singl digit ith
addit clinic support biolog nave patient popul compani expect gain addit share earlier line set
 ell note hile humira gain share eros due novel moa
suggest skyrizi upadacitinib could ramp quickli later-lin set
 forecast conserv peak sale skyrizi upadacitinib vs consensu
currentlt incorpor limit contribut set outsid psoriasi rheumatoid arthriti respect report
skyrizi current investig indic ith upadacitinib
entrench therapi like take time displac continu believ agent superior safety/toler
profil addit strong efficaci data hich help posit respect indic vs competitor still
manag acknow ledg ould take time displac current establish standard carefor exampl pfizer
xeljanz rheumatoid arthriti recent review jak market see biopharmaceut rais ecast bullish jak
survey call today et slide see link
manag encourag venclexta mm efficaci remain confid path forw ard venclexta multipl myeloma
follow ing partial clinic hold imbal death observ phase bellini studi despit clear
evid strong efficaci manag remain confid situat resolv indic remain one
larger sub-typ given efficaci data manag believ venclexta could one first approv biomarker-
associ subpopul space see thought venclexta partial clinic hold
heme/onc franchis outlook remain strong overal expect hematology/ oncolog franchis remain major grow th
driver imbruvica continu ell cll set ith venclexta similarli strong broad r/r populationw ith
addit upsid possibl nhl md manag note pharmacycl acquisit quot potenti
peak revenu forecast despit setback pancreat cancerw hich consid high risk startth compani
continu see potenti grow th franchis current forecast imbruvica sale vs consensu
solid tumor remain major focu remain focus solid tumor key potenti driver manag continu
confid late-stag glioblastoma multiform gbm depatux-m program given strength phase data hile
stemcentrx program experienc setback later-lin settingslead rite-dow nthe trial indic
continu see thought rova-t taho suspens
orilissa launch track well despit challeng build new market report orilissa launch continu show
encourag sign progress manag secur access plan track reach goal still
challeng exist given lack treatment option ith effort on-going activ patient train doctor increas overal
aw arenessespeci ith ith endometriosi current treat ith over-the-counter product pain medic current forecast
revenu vs consensu
competit set help expand market increas awar term potenti tip point manag note
dtc go ell ith good trend observ drug ebsitew ith chang guidelin also like help also
target primari care physician ith mani younger patient opt visit ob/gyn er per year commerci
perspect expect uterin fibroidsand add-back therapyon label time competitor launch overal
compani view entri other posit market term increas aw are build overal potenti
recent coverag market see biopharmaceut omen health survey posit abbv/nbix slide see
market pipelin
hcv outlook remain favor give stabil price share term hcv continu see stabl price
share move forw ard ith access similar approach pariti betw een tw player includ gilead manag continu
confid guidanc year note ere treat patientsw ith estim
year time ill still signific current forecast sale vs con
continu return signific cash sharehold ith regard capit alloc note continu strong
ebidita grow thw ith signific cash reserv return sharehold especi follow ing passag tax reform overal
dividend grow th sinc compani incept leverag standpoint hile decid keep less cash
balanc sheet vs peer given gener cash compani felt flexibl pursu number differ
let us know youv question comment geoff jason olivia greg scott
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu use discount cash flow analysi assum impli intrins
valu per share
risk may imped achiev barclay research valuat price biosimilar make greater
headw ay market cannib share humira could potenti face addit dow nside risk humira current
compris total sale declin drug outlook could sever impact earn addit hcv
portfolio could fail captur share exist competit also imbruvica could limit label expans oncolog
grow th may meet expect pipelin failur could also drive dow nside
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
